Sanjivani Paranteral Ltd. · BSE:SANJIVIN
Sanjivani Paranteral — Q3 FY25 Earnings Presentation
33 slides from Sanjivani Paranteral's earnings presentation, Feb 10, 2025
Slide 1: BSE filing cover letter for investor presentation
Date: 10th February, 2025 To, Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 531569 Sub: Investor Presentation for the Third Quarter ended December 31, 2024. Dear Sir/ Madam, Please find enclosed herewith Investor Presentation of S
Slide 2: Investor Presentation Q3 & 9M FY25
INVESTOR PRESENTATION Q3 & 9M FY25
Slide 3: Table of Content
TABLE OF CONTENT Market Global 04 Overview 19 Footprint About The Product 07 Company 21 Portfolio CDMO Key 13 Clients 25 Financials Company’s Segment 15 & Revenue Mix 31 Stock Information
Slide 4: Key Financial Highlights
Key Financial Highlights Q3 FY25 9M FY25 Rs. In Mn. Revenue from Operations EBIDTA* Revenue from Operations EBIDTA* (up 15.9% Y-o-Y) (up by 29.3% Y-o-Y) (up 25.0% Y-o-Y) (up by 30.2% Y-o-Y) 173.5 28.6 519.2 85.3 PAT Domestic & Export PAT Domestic & Export (up by 15.0% Y-o-Y) (share in revenue) (up b
Slide 5: Market Overview
MARKET OVERVIEW
Slide 6: Global Medicine Market
Global Medicine Market Use of medicines region wise, Defined Daily Doses (DDD) CAGR % Country Name/Year 2018 2019 2020 2021 2022 2023 2024E 2025E 2026E 2027E 2028E 2024-2028 Asia-Pacific 451 461 477 507 547 538 559 580 598 618 637 3.4% Latin America 342 357 438 447 448 461 473 484 489 496 506 1.9% W
Slide 7: Global Medicine Market
Global Medicine Market Defined Daily Doses Global use of Global spending (DDD) in billions medicines on medicine 814 28% 73% 414 14% 35% 2018 2028 2018 2028 2018 2028 Source: IQVIA Institute, Dec 2023. 6
Slide 8: About The Company
ABOUT THE COMPANY
Slide 9: About Us
About Us Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product area
Slide 10: Significant Milestone of Sanjivani
Significant Milestone of Sanjivani 2023 1. Entered into a JV with Alevia Healthcare S.R.O in Prague in May 23 2. Entered into a JV with Hindustan Antibiotics Ltd in August 23 2022 Achieved milestone of adding 100th product in the portfolio 1996 1. Navi Mumbai Plant 2. Listing no BSE April’96 2009 De
Slide 11: Vision, Mission and Values
Vision of the Company To be one of India’s best research-based pharmaceutical companies, through focus on quality VALUES VISION and customer satisfaction. To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & tea
Slide 12: Sanjivani Competitive Advantage
Sanjivani Competitive Advantage We have a compact and highly Our long standing presence in the adaptable presence in India, Rapid decision industry has established us as a allowing us to be exceptionally making capabilities respected leader, making us a nimble and agile preferred partner for top tal
Slide 13: Experienced Management
Experienced Management Mr. Ashwani Khemka Mrs. Mrunmai Sarvankar Mr. Srivardhan Khemka Chairman & Managing Director Director Executive Director Mr. Abhay Shah Ms. Monika A. Singhania Mr. Pritesh Jain Independent Director Independent Director Chief Financial Officer 12
Slide 14: CDMO Key Clients
CDMO KEY CLIENTS
Slide 15: CDMO Key Clients
CDMO Key Clients Injectables Oral & Nutraceuticals 14
Slide 16: Company's Segment & Revenue Mix
COMPANY’S SEGMENT & REVENUE MIX
Slide 17: Product Category Mix (%)
Product Category Mix (%) Q3 FY25 Q3 FY24 0.5% 5.9% 19.6% 13.0% 22.5% 64.1% 74.5% Injectables Tablets Nutraceuticals Injectables Tablets Nutraceuticals Others 9M FY25 9M FY24 1.4% 5.3% 0.8% 40.6% 37.3% 60.5% 54.1% Injectables Tablets Nutraceuticals Injectables Tablets Nutraceuticals Others 16
Slide 18: Geographical Mix (%)
Geographical Mix (%) Q3 FY25 Q3 FY24 15.1% 35.2% 64.8% 84.9% Domestic Exports Domestic Exports 9M FY25 9M FY24 23.5% 27.4% 76.5% 72.6% Domestic Exports Domestic Exports 17
Slide 19: Region-wise Mix (%)
Region-wise Mix (%) Q3 FY25 Q3 FY24 0.6% 1.7% 29.0% 30.2% Latin America 39.5% 36.1% Latin America Middle East & Africa Middle East & Africa India & Subcontinent India & Subcontinent 22.7% 40.2% CIS Countries CIS Countries 9M FY25 9M FY24 0.7% 6.4% Latin America Latin America 23.5% 25.5% 22.8% Middle
Slide 20: Global Footprint
GLOBAL FOOTPRINT
Slide 21: Global Footprint
Global Footprint Prague CIS Countries Dehradun & India Navi Mumbai Central America Latin New Plant America Pimpri Upcoming Manufacturing Dehradun, Navi Mumbai & Prague Plant in Pimpri, Pune 20
Slide 22: Product Portfolio
PRODUCT PORTFOLIO
Slide 23: Product Portfolio
> Product Portfolio SANJIVANI PARANTERAL LTD Bisacody! Tablets BP Smg Nutrisol D35« Vitamin D3 000 IU Tablet ESANJIVANI
Slide 24: Product Portfolio
Product Portfolio Urologics Anesthetics Anesthetics Anti Anti Thyroid Convulsants Agent Anti Anti Anti Anti Anti Anti-lepemic Anti Fungal Emetics Depressants Histamines Diabetic Agent Fibrinolytics Anti-bacterials Anti-spasmodic Anti Vitamin Skeletal Analgesic & Hypertensive Agent Supplement Muscle
Slide 25: Product Portfolio
Product Portfolio Non-opioid Antacids Antiseptics Nsaids Corticosteroids Analgesics Diuretics Immunosupress Narcotic Hormone Topical Anti Anxiety ants Corticosteroids Antibiotic Antipsychotic Anti Viral Narcotics Anti- Muscle Relaxant 24
Slide 26: Financials
FINANCIALS
Slide 27: Segment-wise Revenue
Segment-wise Revenue (Injectables, Oral & Nutraceuticals) Rs. In Mn. INJECTABLES ORALS 129.2 77.3 95.8 90.7 33.6 34.1 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 NUTRACEUTICALS 13.4 10.2 1.9 Q3FY24 Q2FY25 Q3FY25 26
Slide 28: Quarterly Financials
Quarterly Financials - Revenue, EBITDA & Margin, PAT & Margin Rs. In Mn. REVENUE* EBIDTA** & EBIDTA Margin 181 174 17.2% 164 16.5% 150 14.7% 129 13.1% 17.9% 20 22 24 32 29 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 PBT & PBT Margin PAT & PAT Margin 29 14.2% 14.6% 25 19 23
Slide 29: Q3 & 9M FY25 Profit & Loss Statement
Q3 & 9M FY25 Profit & Loss Statement Particulars (Rs. In Mn.) Q3 FY25 Q3 FY24 YoY% Q2 FY25 QoQ% 9M FY25 9M FY24 YoY% FY24 Revenue From Operations 173.5 149.6 15.9% 181.3 -4.3% 519.2 415.5 25.0% 544.1 Other Income 3.1 2.5 22.6% 3.9 -19.9% 7.9 4.6 69.3% 5.2 Total Income 176.6 152.2 16.1% 185.2 -4.6% 5
Slide 30: Yearly Financials
Yearly Financials Revenue, EBITDA & Margin, PAT & Margin Rs. In Mn. REVENUE* EBIDTA** & EBIDTA Margin 544 519 19.5% 17.4% 16.1% 16.4% 355 306 60 62 88 85 FY22 FY23 FY24 9MFY25 FY22 FY23 FY24 9MFY25 PAT & PAT Margin EPS In Rs. 5.3 15.7% 5.1 12.5% 11.2% 11.2% 4.9 4.5 48 45 62 59 FY22 FY23 FY24 9MFY25
Slide 31: Long Term Growth Drivers
Long Term Growth Drivers Expand Product 1 Portfolio Strategic partnerships 2 & Collaborations Expand into 3 New Geographies Therapeutic 4 Diversification 30
Slide 32: Stock Information
Stock Information Shareholding Pattern as on 31st December 2024 Stock Information (as on 31st December 2024) Market Cap. (in crores) 454 27.7 37.0 Stock Price 388.5 6.3 52 Week (High / Low) 388.5 / 126.7 20.6 8.5 BSE – Symbol 531569 Free Float (No. of Shares) 84,51,239 Promoter Institutions HNI Corp
Slide 33: Thank You
THANK YOU Sanjivani Paranteral Limited 205, P.N.Kothari Industrial Estate, L.B.S. Marg Bhandup (W), Mumbai- 400078, India. Ph: +91-22-20812600 / 25620515 Email: [email protected] Jill Chandrani +91 7506023955 Email: [email protected] 215, Shivshakti Industrial Estate, J.R Boricha Marg, Lower